Evid Based Nurs 7:49 doi:10.1136/ebn.7.2.49
  • Treatment

Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women

 Q Does oestrogen plus progestogen reduce the risk of coronary heart disease (CHD) in postmenopausal women?



randomised placebo controlled trial.




blinded {patients, clinicians, data collectors, outcome assessors, and monitoring committee}*.

GraphicFollow up period:

mean 5.6 years.


{40 clinical centres in the US}*.


16 608 postmenopausal women who were 50–79 years of age (mean age 63 y), had an intact uterus, and resided in the same geographic area for ⩾3 years.


1 daily tablet of oral conjugated equine oestrogen, 0.625 mg, plus medroxyprogesterone acetate (Prempro, Wyeth Ayerst, Philadelphia, PA, USA), 2.5 mg, (n = 8506) or placebo (n = 8102).


CHD defined as acute myocardial infarction (MI) requiring overnight admission to hospital, death caused by CHD, or silent MI identified on serial electrocardiography. Secondary outcomes included coronary revascularisation, confirmed angina, and …

No Related Web Pages

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article